Ludovic Helfgott/LinkedIn
Nov 15, 2025, 15:45
Ludovic Helfgott: Researchers Have Analysed Novo Nordisk Product Data in Obesity and Cardiovascular Disease
Ludovic Helfgott, Executive Vice President, Product and Portfolio Strategy at Novo Nordisk, shared a post on LinkedIn:
“New paper in The Lancet Group today. Researchers have analysed Novo Nordisk product data in obesity and cardiovascular disease and the results suggest that a reduction of major adverse cardiovascular events in people with overweight or obesity is independent of baseline weight and weight loss.
These findings again support our strategy to reduce the risk of cardiovascular events for the hundreds of millions of people living with overweight or obesity and cardiovascular disease and promote their long-term health.”
Stay updated with Hemostasis Today.
-
Dec 16, 2025, 16:14Nicolas Gendron on Sustainability in Anticoagulation and DOACs
-
Dec 16, 2025, 15:39Reza Shojaei: Every Expired Unit of Blood Tells a Story
-
Dec 16, 2025, 14:03Francesco Lo Monaco on Rethinking Blood Pressure: The Major Problem with How We Understand It
-
Dec 16, 2025, 14:03Marilena Vrana Urges EU Policymakers to “Keep Patients at the Centre” of Critical Medicines Act
-
Dec 16, 2025, 14:02Even Distribution of Protective Hemoglobin Prevents Sickle Cell Symptoms
-
Dec 16, 2025, 13:58AHA Awards Shubham Misra Postdoc Grant for LVO Stroke Biomarker Research
-
Dec 16, 2025, 13:00ScholarGPS Ranks Emmanuel J. Favaloro No. 1 in the World for Hemostasis
-
Dec 16, 2025, 11:30Kingsley Wheaton: Sweden is on the Brink of Becoming the World’s 1st Smoke-Free Country
-
Dec 16, 2025, 11:03Matías J Alet on CABOS Project with The Support of WSO